---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000008"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T20:33:17.954812+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada closes $224M upfront Vertex collaboration for DM1; cash runway to H2 2025

## Summary
- Closed global collaboration with Vertex for ENTR-701 and other DM1 research; Vertex leads development.
- Received $224M upfront plus $26M equity investment at $16.26 per share (1,618,613 shares).
- Eligible for up to $485M in research, development, regulatory, and commercial milestones.
- Entitled to tiered royalties on future net sales of any products from the collaboration.
- Proceeds extend cash runway into second half of 2025, funding DMD and other EEV programs.

## SEC filing metadata
- accession: 0001689375-23-000008
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000008/0001689375-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000008/trda-20230209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000008
- JSON: https://secwatch.observer/filing/0001689375-23-000008.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.